{
    "clinical_study": {
        "@rank": "48825", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with\n      early-stage bladder cancer that has not responded to BCG therapy."
        }, 
        "brief_title": "Chemotherapy in Treating Patients With Early-Stage Bladder Cancer", 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the recurrence rate and disease free survival in patients with recurrent or\n           refractory papillary transitional cell carcinoma of the bladder with or without\n           carcinoma in situ of the bladder treated with intravesical AD 32.\n\n        -  Evaluate the safety of administering this drug in these patients.\n\n        -  Determine the effectiveness of this drug, in terms of recurrence rates and disease free\n           survival, in these patients.\n\n      OUTLINE: Patients are stratified according to cellular diagnosis (papillary transitional\n      cell carcinoma (Ta/T1) with no carcinoma in situ (Tis) vs Tis with or without Ta/T1).\n\n      Patients receive intravesical AD 32 once a week for 6 weeks.\n\n      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then\n      annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed recurrent superficial bladder cancer defined as papillary\n             transitional cell carcinoma (stage Ta/T1) and/or carcinoma in situ (stage Tis) of the\n             urinary bladder\n\n               -  No evidence of invasion of the underlying muscle (stage T2) at baseline\n\n          -  Must meet 1 of the following criteria:\n\n               -  Failure of at least 2 prior courses of intravesical therapy, 1 of which must\n                  have been a course of BCG\n\n               -  Recurrent or persistent disease within 6 months after failing a 6-week course of\n                  BCG followed by maintenance therapy\n\n               -  Inability or ineligibility to complete 1 course of intravesical therapy with\n                  BCG, and failure of 2 prior courses of intravesical therapy with an alternative\n                  agent\n\n          -  Diagnosis must have been made no more than 24 months after completion of prior\n             treatment with intravesical immunotherapy or chemotherapy\n\n          -  If carcinoma in situ is current or previous diagnosis, the biopsies must be obtained\n             from at least 4 sites (bladder mapping)\n\n          -  If prostatic urothelial biopsy discloses carcinoma in situ, transurethral prostatic\n             resection must be carried out prior to study\n\n          -  Papillary disease must have undergone complete transurethral resection (TURBT) within\n             28 days before study\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-1\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC greater than 4,000/mm^3\n\n          -  Platelet count greater than 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2 times upper limit of normal (ULN)\n\n          -  SGOT and SGPT less than 3 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2.5 mg/dL\n\n        Other:\n\n          -  Normal upper tract (ureter and renal pelvic) evaluation within 6 months\n\n          -  No known sensitivity to anthracyclines or to Cremophor EL\n\n          -  HIV negative\n\n          -  No known AIDS or HIV-1 associated complex\n\n          -  No other significant concurrent illness\n\n          -  No other prior malignancy within the past 3 years except superficial bladder cancer,\n             adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of\n             the cervix\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n          -  No concurrent biological response modifier therapy\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  Prior oral bropirimine for bladder cancer allowed\n\n          -  No prior AD 32 for bladder cancer\n\n          -  No other intravenously administered systemic chemotherapy for bladder cancer\n\n          -  No concurrent chemotherapy for any other malignancy\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy\n\n        Radiotherapy:\n\n          -  No prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003129", 
            "org_study_id": "CDR0000065892", 
            "secondary_id": "E-3897"
        }, 
        "intervention": {
            "intervention_name": "valrubicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Valrubicin"
        }, 
        "keyword": [
            "stage 0 bladder cancer", 
            "stage I bladder cancer", 
            "transitional cell carcinoma of the bladder"
        ], 
        "lastchanged_date": "June 6, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/E-3897"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612-9497"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urbana", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61801"
                    }, 
                    "name": "CCOP - Carle Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Orange", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07018-1095"
                    }, 
                    "name": "Veterans Affairs Medical Center - East Orange"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wynnewood", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19096"
                    }, 
                    "name": "CCOP - MainLine Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Green Bay", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "54301"
                    }, 
                    "name": "CCOP - Green Bay"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792-6164"
                    }, 
                    "name": "University of Wisconsin Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53705"
                    }, 
                    "name": "Veterans Affairs Medical Center - Madison"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53295"
                    }, 
                    "name": "Veterans Affairs Medical Center - Milwaukee (Zablocki)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin", 
        "overall_official": {
            "affiliation": "NorthShore University HealthSystem Research Institute", 
            "last_name": "Jeffrey M. Ignatoff, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003129"
        }, 
        "results_reference": {
            "PMID": "18639470", 
            "citation": "Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2008 Jul 16; [Epub ahead of print]"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Eastern Cooperative Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2002"
    }, 
    "geocoordinates": {
        "CCOP - Carle Cancer Center": "40.111 -88.207", 
        "CCOP - Green Bay": "44.519 -88.02", 
        "CCOP - MainLine Health": "39.989 -75.277", 
        "Fox Chase Cancer Center": "39.952 -75.164", 
        "H. Lee Moffitt Cancer Center and Research Institute": "27.951 -82.457", 
        "Medical College of Wisconsin": "43.039 -87.906", 
        "University of Wisconsin Comprehensive Cancer Center": "43.073 -89.401", 
        "Veterans Affairs Medical Center - East Orange": "40.767 -74.205", 
        "Veterans Affairs Medical Center - Madison": "43.073 -89.401", 
        "Veterans Affairs Medical Center - Milwaukee (Zablocki)": "43.039 -87.906"
    }
}